[Preventive treatments of tachycardias in Wolff-Parkinson-White syndrome].
Tachycardias in Wolff-Parkinson-White syndrome are due to the presence of an accessory conduction pathway between atria and ventricles. Many patients are treated with anti-arrhythmic drugs alone or in combinations. In difficult cases, the choice of therapy is guided by investigatory methods using Holter's recording system and intracavitary electrophysiological techniques, sometimes associated with special pacemakers arresting reciprocal rhythm. Intolerance to such pacemakers or failure of medical treatments usually leads to surgery. Division of the accessory conduction pathway constitutes a radical treatment of the syndrome with satisfactory results when performed by trained teams.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000379:methods; D004594:Electrophysiology; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000601:surgery; D006801:Humans; D010138:Pacemaker, Artificial; D013610:Tachycardia / Q000209:etiology / Q000517:prevention & control*; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications / Q000628:therapy*
D000889:Anti-Arrhythmia Agents
Stratégie du traitement préventif des tachycareies du syndrome de Wolff-Parkinson-White.